Predictive factors for pathologic complete response (pCR) to trastuzumab (T)-based neoadjuvant chemotherapy in HER2+ breast cancer (BC) women treated in the National Cancer Institute (NCI) of Mexico.
Erika Sifuentes
No relevant relationships to disclose
Yanin Chavarri Guerra
No relevant relationships to disclose
F. Berenice Baez-Revueltas
No relevant relationships to disclose
Enrique Soto-Perez-de-Celis
No relevant relationships to disclose
Fernando Lara-Medina
No relevant relationships to disclose
Santiago Ruano
No relevant relationships to disclose
Cynthia Mayte Villarreal-Garza
No relevant relationships to disclose